Business
Almirall taps CrystalO's AI platform to discover ion channel drugs for skin disease
Barcelona-based Almirall, S.A. (ALM) and China-based Shenzhen CrystalO Biopharma Technology Co., Ltd. have announced a collaboration and licensing agreement...
Sobi funds Innate's phase III lacutamab trial with USD 75 million upfront deal
Marseille-based Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI) announced a strategic...
Novo Nordisk taps AWS as preferred cloud provider, launches London AI drug discovery hub
Novo Nordisk (Copenhagen: NOVO B) and Amazon Web Services (AWS) announced a strategic partnership that establishes AWS as Novo Nordisk's preferred cloud...
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) and Revolution Medicines, Inc. (Nasdaq: RVMD) announced a two-part arrangement covering both...
Acurx and Leiden University Medical Center target first inhibitor-bound MRSA PolC structure
Staten Island, New York-based Acurx Pharmaceuticals (Nasdaq: ACXP) announced a new scientific research partnership with Netherlands-based Leiden University...
Jazz moves on Actio Bio for up to USD 1.3b to enter KCNT1-driven epilepsy market
Jazz Pharmaceuticals (Nasdaq: JAZZ) has agreed to acquire San Diego-based Actio Biosciences, Inc. for USD 820 million upfront plus up to USD 500 million in...
Vedanta secures USD 60m ahead of Phase III VE303 recurrent C. difficile readout
Cambridge, Massachusetts-based Vedanta Biosciences, a late clinical-stage company developing microbiome-based oral therapies for gastrointestinal disease,...
HanchorBio partners with Taiwan Cancer Moonshot to guide FBDB pipeline with multi-omics biomarkers
HanchorBio, Inc. (TWSE: 7827), the clinical-stage biotechnology company headquartered in Taipei, Shanghai, and the San Francisco Bay Area, announced a...
BeOne Q2'26: RAS-ON ADC unveiled as five solid tumor programs race toward Phase III
BeOne Medicines Q2 2026 earnings call, held on August 5, 2026, was defined by two competing narratives: a deepening evidence base for zanubrutinib...
Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership
San Diego-based Arcturus Therapeutics (Nasdaq: ARCT) has terminated its self-amplifying mRNA collaboration with CSL Seqirus through a settlement agreement,...
BioMarin drops BMN 401 following unsuccessful pivotal trial
BioMarin Discontinues BMN 401 Across All Indications After Pivotal ENPP1 Trial Fails Co-Primary Endpoints
Shape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation
Seattle-based Shape Therapeutics and the Rett Syndrome Research Trust (RSRT) announced a partnership to advance SHP-401, an investigational RNA editing gene...
Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline
Irvine, California-based Tarsus Pharmaceuticals (Nasdaq: TARS) announced an oversubscribed USD 125 million private investment in public equity (PIPE)...
ReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner
Mountain View, California-based ReCode Therapeutics announced a research collaboration with an undisclosed gene editing company to develop a CFTR-correcting...
Biogen closes deal for USD 1b buyout of RayThera
Biogen (Nasdaq: BIIB) has completed its acquisition of RayThera Inc., a San Diego-based small-molecule immunology company, for a total potential...
The AllSci Brief
Free, systematic R&D and deal news. Daily.